Chronological ageing and ovarian reserve in MS: insights from anti-Müllerian hormone and disability progression

BACKGROUND: Accelerated biological ageing has been proposed as a key mechanism influencing disease progression in multiple sclerosis. Anti-Müllerian hormone (AMH), a marker of ovarian reserve, may reflect biological ageing in women and could be associated with disability progression. We aim to evaluate the prognostic implications of AMH levels measured at the first demyelinating event (FDE) suggestive of multiple sclerosis (MS). METHODS: This retrospective study analysed prospectively collected data from three Spanish neuroimmunology centres (since 1994). It included 365 females aged 20-45 years with serum AMH measured within 2 years of onset. According to AMH tertiles (n, median ng/mL (range)), participants were classified as follows: high (n=121; 4.6 (3.2-17.4)), medium (n=122; 2.1 (1.3-3.2)) and low (n=121; 0.6 (0.01-1.3)). A total of 145 healthy females served as controls. Age-adjusted multivariable linear regression models assessed associations between AMH and baseline clinical, radiological and serum biomarkers. Cox regression models evaluated the risk of Expanded Disability Status Scale 3.0, second relapse, progression independent of relapse activity and relapse-associated worsening. RESULTS: At FDE, median (range) age was 32.9 (22.2-44.9) years, follow-up 6.5 years (0.01-29.4) and AMH 2.2 (0.01-17.4); 68% received disease-modifying treatment. AMH levels did not differ between patients and controls and were inversely correlated with chronological age (β -1.21 (95% CI -1.42 to -1.00), p<0.001). After adjustment for chronological age, AMH showed no independent association with clinical, radiological or biomarker measures, or long-term outcomes. CONCLUSIONS: AMH levels at the time of an FDE suggestive of MS were not associated with baseline activity or long-term outcomes related to relapses or disability. Our findings suggest that the apparent associations between AMH and disease characteristics are largely driven by chronological age, supporting the concept that ovarian reserve primarily reflects biological ageing rather than an independent determinant of MS progression.

Authors

Institutions

Publication Details

Journal
Journal of Neurology Neurosurgery & Psychiatry
Published
2026-06-24
DOI
https://doi.org/10.1136/jnnp-2026-338790
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Chronological ageing and ovarian reserve in MS: insights from anti-Müllerian hormone and disability progression

Neus Mongay‐Ochoa, Andreu Vilaseca-Jolonch, Mireia Castillo, Jaume Sastre‐Garriga et al.
Journal of Neurology Neurosurgery & Psychiatry
Multiple Sclerosis Research Studies
article

Chronological ageing and ovarian reserve in MS: insights from anti-Müllerian hormone and disability progression

Neus Mongay‐Ochoa, Andreu Vilaseca-Jolonch, Mireia Castillo, Jaume Sastre‐Garriga, Ignacio Arribas, Carmen Tur, Juan Pablo Cuello, Irene Ruiz-Pérez, Álvaro Cobo‐Calvo, Helena Ariño, René Carvajal, Xavier Montalbán, Luca Bollo, Susana Sainz de la Maza, Haydee Goicochea-Briceño, Mar Tintoré, Enric Monreal, Ana Gómez Lozano, José Ignacio Fernández-Velasco, Alexander Rodero-Romero, Ana Zabalza, Ángela Vidal‐Jordana, Àlex Rovira, Noelia Villarrubia, Melchor Carbonell, Julio Herrero, Javier Villacieros‐Álvarez, Ariana Meldaña Rivera, Virginia Ortega Abad, Lucienne Costa‐Frossard, Georgina Arrambide, Jordi Río, Agustín Pappolla, Manuel Comabella, Joaquín Castilló, J M García-Domínguez, Ana Maria Garcı́a, C Moliner Sanchez, S. Otero, Elena Carreras, R F Ferrer, Luciana Midaglia, Ingrid Galán, Noelia Díaz-Troyano, Pilar Reimundo, Breogán Rodríguez-Acevedo, María Luisa Martínez-Gines, Juan De León-Luis, Yolanda Higueras, M Luisa Villar
article en

Abstract

BACKGROUND: Accelerated biological ageing has been proposed as a key mechanism influencing disease progression in multiple sclerosis. Anti-Müllerian hormone (AMH), a marker of ovarian reserve, may reflect biological ageing in women and could be associated with disability progression. We aim to evaluate the prognostic implications of AMH levels measured at the first demyelinating event (FDE) suggestive of multiple sclerosis (MS). METHODS: This retrospective study analysed prospectively collected data from three Spanish neuroimmunology centres (since 1994). It included 365 females aged 20-45 years with serum AMH measured within 2 years of onset. According to AMH tertiles (n, median ng/mL (range)), participants were classified as follows: high (n=121; 4.6 (3.2-17.4)), medium (n=122; 2.1 (1.3-3.2)) and low (n=121; 0.6 (0.01-1.3)). A total of 145 healthy females served as controls. Age-adjusted multivariable linear regression models assessed associations between AMH and baseline clinical, radiological and serum biomarkers. Cox regression models evaluated the risk of Expanded Disability Status Scale 3.0, second relapse, progression independent of relapse activity and relapse-associated worsening. RESULTS: At FDE, median (range) age was 32.9 (22.2-44.9) years, follow-up 6.5 years (0.01-29.4) and AMH 2.2 (0.01-17.4); 68% received disease-modifying treatment. AMH levels did not differ between patients and controls and were inversely correlated with chronological age (β -1.21 (95% CI -1.42 to -1.00), p<0.001). After adjustment for chronological age, AMH showed no independent association with clinical, radiological or biomarker measures, or long-term outcomes. CONCLUSIONS: AMH levels at the time of an FDE suggestive of MS were not associated with baseline activity or long-term outcomes related to relapses or disability. Our findings suggest that the apparent associations between AMH and disease characteristics are largely driven by chronological age, supporting the concept that ovarian reserve primarily reflects biological ageing rather than an independent determinant of MS progression.

Journal of Neurology Neurosurgery & Psychiatry
Hebron University (PS), Universitat Autònoma de Barcelona (ES), Hospital General Universitario Gregorio Marañón (ES), Vall d'Hebron Institut de Recerca (ES), Vall d'Hebron Hospital Universitari (ES), Hospital Universitari Germans Trias i Pujol (ES), Hospital Universitario Ramón y Cajal (ES)
Good health and well-being
Openalex Percentile: Top 7%
Multiple Sclerosis Research Studies
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.